Ken Griffin Agios Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 9,400 shares of AGIO stock, worth $331,068. This represents 0.0% of its overall portfolio holdings.

Number of Shares

9,400

Previous 12,700 25.98%

Holding current value

$331,068

Previous $564,000 45.39%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$32.86 - $61.64 $46.7 Million - $87.6 Million	1,421,940 Added 12116.05%	1,433,676 $47.1 Million
Q3 2024 Nov 14, 2024	SELL	$41.19 - $49.72 $4.62 Million - $5.57 Million	-112,104 Reduced 90.52%	11,736 $521,000
Q2 2024 Aug 14, 2024	SELL	$27.55 - $48.83 $24.2 Million - $42.9 Million	-878,621 Reduced 87.65%	123,840 $5.34 Million
Q1 2024 May 15, 2024	SELL	$21.32 - $34.81 $1.54 Million - $2.52 Million	-72,351 Reduced 6.73%	1,002,461 $29.3 Million
Q4 2023 Feb 14, 2024	BUY	$19.97 - $24.53 $13.1 Million - $16.1 Million	658,194 Added 157.99%	1,074,812 $23.9 Million
Q3 2023 Nov 14, 2023	BUY	$24.36 - $28.18 $5.88 Million - $6.8 Million	241,427 Added 137.81%	416,618 $10.3 Million
Q2 2023 Aug 14, 2023	SELL	$21.38 - $29.19 $2.31 Million - $3.15 Million	-107,963 Reduced 38.13%	175,191 $4.96 Million
Q1 2023 May 15, 2023	BUY	$21.74 - $30.93 $1.39 Million - $1.98 Million	64,137 Added 29.28%	283,154 $6.5 Million
Q4 2022 Feb 14, 2023	SELL	$24.81 - $31.52 $760,054 - $965,615	-30,635 Reduced 12.27%	219,017 $6.15 Million
Q3 2022 Nov 14, 2022	SELL	$19.51 - $34.14 $1.64 Million - $2.87 Million	-83,929 Reduced 25.16%	249,652 $7.06 Million
Q2 2022 Aug 15, 2022	BUY	$17.06 - $31.42 $5.15 Million - $9.48 Million	301,818 Added 950.22%	333,581 $7.4 Million
Q1 2022 May 16, 2022	BUY	$26.68 - $34.81 $307,727 - $401,498	11,534 Added 57.02%	31,763 $925,000
Q4 2021 Feb 14, 2022	SELL	$29.58 - $49.78 $2.31 Million - $3.9 Million	-78,253 Reduced 79.46%	20,229 $664,000
Q3 2021 Nov 15, 2021	SELL	$41.92 - $58.18 $3.41 Million - $4.74 Million	-81,391 Reduced 45.25%	98,482 $4.55 Million
Q1 2021 May 17, 2021	BUY	$44.23 - $57.5 $7.03 Million - $9.15 Million	159,051 Added 763.86%	179,873 $9.29 Million
Q4 2020 Feb 16, 2021	SELL	$33.21 - $46.54 $6.03 Million - $8.45 Million	-181,609 Reduced 89.71%	20,822 $902,000
Q3 2020 Nov 16, 2020	BUY	$33.87 - $55.93 $3.35 Million - $5.54 Million	99,032 Added 95.78%	202,431 $7.09 Million
Q2 2020 Aug 14, 2020	SELL	$34.45 - $53.48 $13.1 Million - $20.4 Million	-381,542 Reduced 78.68%	103,399 $5.53 Million
Q1 2020 May 15, 2020	BUY	$31.52 - $53.81 $7.58 Million - $12.9 Million	240,568 Added 98.44%	484,941 $17.2 Million
Q4 2019 Feb 14, 2020	SELL	$30.08 - $50.59 $3.35 Million - $5.64 Million	-111,529 Reduced 31.34%	244,373 $11.7 Million
Q3 2019 Nov 14, 2019	SELL	$32.4 - $49.58 $8.92 Million - $13.6 Million	-275,156 Reduced 43.6%	355,902 $11.5 Million
Q2 2019 Aug 14, 2019	BUY	$46.17 - $68.1 $9.54 Million - $14.1 Million	206,570 Added 48.66%	631,058 $31.5 Million
Q1 2019 May 15, 2019	BUY	$45.92 - $67.67 $6.58 Million - $9.69 Million	143,253 Added 50.94%	424,488 $0
Q4 2018 Feb 14, 2019	BUY	$42.73 - $76.53 $4.89 Million - $8.75 Million	114,345 Added 68.52%	281,235 $13 Million
Q3 2018 Nov 13, 2018	BUY	$71.67 - $91.95 $11.7 Million - $15 Million	163,389 Added 4666.92%	166,890 $0
Q2 2018 Aug 10, 2018	SELL	$73.22 - $99.55 $1.09 Million - $1.48 Million	-14,854 Reduced 80.93%	3,501 $0
Q1 2018 May 11, 2018	SELL	$59.83 - $86.53 $4.37 Million - $6.33 Million	-73,115 Reduced 79.93%	18,355 $1.5 Million
Q4 2017 Feb 09, 2018	BUY	$52.12 - $72.33 $4.77 Million - $6.62 Million	91,470	91,470 $5.23 Million

Others Institutions Holding AGIO

# of Institutions

244

Shares Held

59.9M

Call Options Held

270K

Put Options Held

332K

View Full List

About AGIOS PHARMACEUTICALS, INC.

Ticker AGIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,818,000
Market Cap $1.93B
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...

More about AGIO

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account